Oncology · 1 h ago
PFDN2 expression is linked to aggressive features in hepatocellular carcinoma
A study of 265 hepatocellular carcinoma specimens found that high PFDN2 expression was associated with poorer overall and recurrence-free survival. Cell experiments also linked PFDN2 to migration-related signaling, but the findings do not establish a validated clinical risk-stratification tool.
- High PFDN2 was associated with vascular invasion and poor differentiation.
- High expression was linked to worse overall and recurrence-free survival.
- Cell experiments linked PFDN2 to migration and proliferation-related findings.
Researchers assessed prefoldin subunit protein expression in tissue microarrays from 265 hepatocellular carcinoma (HCC) specimens and examined associations with clinicopathological features and survival. They also tested PFDN2 function in Huh7 cells with overexpression and HLF cells with knockdown, measuring migration, invasion, proliferation and signaling markers.
High PFDN2 expression was associated with poor tumor differentiation and vascular invasion. It was also associated with worse overall survival (p=0.0257) and recurrence-free survival (p=0.0255). In cell experiments, overexpression increased migration and lamellipodia formation alongside changes in Rac1-associated signaling proteins. Knockdown suppressed proliferation and increased endoplasmic-reticulum stress markers.
The results suggest a possible link between PFDN2 and aggressive HCC biology. However, the evidence combines tissue-based associations with in vitro experiments; the source does not report validation of PFDN2 as a prognostic test or show that using it would improve postoperative decisions.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: Prefoldin Subunit 2 Promotes Migration of Hepatocellular Carcinoma Cells and Is Associated with Poor Prognosis ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.